Leerink Partnrs Brokers Lift Earnings Estimates for Cryoport

Cryoport, Inc. (NASDAQ:CYRX - Free Report) - Analysts at Leerink Partnrs increased their Q2 2025 earnings per share estimates for Cryoport in a research report issued to clients and investors on Wednesday, May 7th. Leerink Partnrs analyst P. Souda now expects that the company will post earnings per share of ($0.21) for the quarter, up from their previous estimate of ($0.22). The consensus estimate for Cryoport's current full-year earnings is ($0.99) per share. Leerink Partnrs also issued estimates for Cryoport's Q3 2025 earnings at ($0.21) EPS, Q4 2025 earnings at ($0.17) EPS, FY2025 earnings at ($0.76) EPS and FY2026 earnings at ($0.77) EPS.

Cryoport (NASDAQ:CYRX - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.01. The company had revenue of $41.04 million for the quarter, compared to analyst estimates of $56.19 million. Cryoport had a negative return on equity of 13.35% and a negative net margin of 70.08%.

Several other equities analysts have also issued reports on the company. Roth Mkm reaffirmed a "buy" rating and set a $15.00 price objective on shares of Cryoport in a report on Tuesday, April 1st. Morgan Stanley lowered their price target on Cryoport from $8.00 to $7.00 and set an "equal weight" rating on the stock in a report on Monday, May 5th. Needham & Company LLC reissued a "buy" rating and set a $11.00 price target on shares of Cryoport in a report on Thursday, May 8th. Guggenheim reissued a "buy" rating and set a $10.00 price target on shares of Cryoport in a report on Wednesday, April 16th. Finally, UBS Group raised their price target on Cryoport from $10.00 to $11.00 and gave the stock a "buy" rating in a report on Tuesday, April 1st. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, Cryoport currently has a consensus rating of "Moderate Buy" and a consensus price target of $11.00.

Cryoport Stock Performance

Shares of CYRX stock traded up $0.13 during mid-day trading on Monday, hitting $6.86. 98,993 shares of the stock were exchanged, compared to its average volume of 541,156. The stock's fifty day simple moving average is $5.95 and its two-hundred day simple moving average is $6.86. The stock has a market capitalization of $344.14 million, a price-to-earnings ratio of -2.04 and a beta of 1.92. Cryoport has a 12-month low of $4.58 and a 12-month high of $14.20. The company has a debt-to-equity ratio of 0.48, a quick ratio of 5.32 and a current ratio of 5.70.

Insider Activity at Cryoport

In related news, CEO Jerrell Shelton sold 4,620 shares of the firm's stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $6.29, for a total value of $29,059.80. Following the completion of the sale, the chief executive officer now owns 765,399 shares in the company, valued at $4,814,359.71. This trade represents a 0.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders sold a total of 19,830 shares of company stock worth $118,353 over the last 90 days. Company insiders own 10.00% of the company's stock.

Institutional Investors Weigh In On Cryoport

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Jacobs Levy Equity Management Inc. lifted its position in shares of Cryoport by 54.0% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 113,235 shares of the company's stock valued at $688,000 after acquiring an additional 39,698 shares during the period. Banque Transatlantique SA acquired a new stake in shares of Cryoport during the 1st quarter valued at approximately $369,000. AQR Capital Management LLC lifted its position in shares of Cryoport by 285.5% during the 1st quarter. AQR Capital Management LLC now owns 262,596 shares of the company's stock valued at $1,597,000 after acquiring an additional 194,482 shares during the period. Cubist Systematic Strategies LLC lifted its position in shares of Cryoport by 109.6% during the 1st quarter. Cubist Systematic Strategies LLC now owns 226,457 shares of the company's stock valued at $1,377,000 after acquiring an additional 118,420 shares during the period. Finally, Trexquant Investment LP lifted its position in shares of Cryoport by 57.7% during the 1st quarter. Trexquant Investment LP now owns 377,127 shares of the company's stock valued at $2,293,000 after acquiring an additional 137,989 shares during the period. 92.90% of the stock is currently owned by institutional investors and hedge funds.

About Cryoport

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.